COST-EFFECTIVENESS OF THE BIVALENT RESPIRATORY SYNCYTIAL VIRUS PREFUSION F (RSVPREF) VACCINE IN AT-RISK ADULTS AGED =60 YEARS IN PERU
Author(s)
Tomas Eduardo Abbott, MSc.1, Jazmin Rosario Figueroa, MD2, Norka Napuri, MD2, Ali Shajarizadeh, PhD3, Nishu Gaind, MBA3, Luka Ivkovic, MSc.3, Gopika Balasubramanian, MSc.3, Rengina Kefalogianni, MSc.4, Diana Mendes, PhD.4.
1Pfizer Chile S.A., Santiago, Chile, 2Pfizer Medical Affairs SoLA Cluster, Lima, Peru, 3Evidinno Outcomes Research Inc., Vancouver, BC, Canada, 4Pfizer Ltd., Tadworth, United Kingdom.
1Pfizer Chile S.A., Santiago, Chile, 2Pfizer Medical Affairs SoLA Cluster, Lima, Peru, 3Evidinno Outcomes Research Inc., Vancouver, BC, Canada, 4Pfizer Ltd., Tadworth, United Kingdom.
OBJECTIVES: Respiratory Syncytial Virus (RSV)-associated lower respiratory tract infection among adults causes substantial morbidity, mortality, and healthcare costs, particularly those with risk factors for severe disease or immunocompromising conditions. The Peruvian Society of Pneumology has recommended single-dose vaccination against RSV for adults aged ≥60 years and those with underlying conditions (at-risk). This study assessed the cost-effectiveness of the bivalent RSVpreF versus no vaccination for at-risk adults aged ≥60 years from the Peruvian public payer perspective.
METHODS: A Markov cohort model projected lifetime clinical and economic outcomes in 1,914,443 at-risk adults aged ≥60 years. Inputs were obtained from published literature and official government sources. Vaccine effectiveness against RSV-related hospitalizations, emergency department (ED) visits, and outpatient (PO) visits was informed by published two-season real-world effectiveness and efficacy data. Uptake was assumed at 61% based on 2025 influenza vaccine coverage in Peru. Vaccine cost was assumed US$49.00 (S/174.79) per dose (PAHO Revolving Fund). Costs were reported in 2025 US dollars and Peruvian Soles; costs and outcomes were discounted at 3% annually. Scenario and sensitivity analyses assessed robustness.
RESULTS: Without vaccination, RSV was projected to cause 80,435 hospitalizations, 343,423 ED visits, 1,732,769 PO visits, and 7,365 deaths over the cohort lifetime, corresponding to US$401 million (S/1,432 million) in direct medical costs to the health system. At 61% uptake, 1,167,810 individuals received RSVpreF. Vaccination averted 7,295 hospitalizations, 34,972 ED visits, 79,982 PO visits, and 614 deaths, generating 2,623 QALYs. RSVpreF reduced RSV-related direct medical costs by US$44 million (S/157 million). After vaccination costs and medical cost offsets, incremental costs were US$17 million (S/61 million), yielding an ICER of US$6,567/QALY (S/23,425), below Peru’s threshold of US$7,011/QALY (S/25,007).
CONCLUSIONS: RSVpreF is projected to reduce RSV-related clinical and economic burden and be cost-effective versus no vaccination among at-risk adults aged ≥60 years in Peru.
METHODS: A Markov cohort model projected lifetime clinical and economic outcomes in 1,914,443 at-risk adults aged ≥60 years. Inputs were obtained from published literature and official government sources. Vaccine effectiveness against RSV-related hospitalizations, emergency department (ED) visits, and outpatient (PO) visits was informed by published two-season real-world effectiveness and efficacy data. Uptake was assumed at 61% based on 2025 influenza vaccine coverage in Peru. Vaccine cost was assumed US$49.00 (S/174.79) per dose (PAHO Revolving Fund). Costs were reported in 2025 US dollars and Peruvian Soles; costs and outcomes were discounted at 3% annually. Scenario and sensitivity analyses assessed robustness.
RESULTS: Without vaccination, RSV was projected to cause 80,435 hospitalizations, 343,423 ED visits, 1,732,769 PO visits, and 7,365 deaths over the cohort lifetime, corresponding to US$401 million (S/1,432 million) in direct medical costs to the health system. At 61% uptake, 1,167,810 individuals received RSVpreF. Vaccination averted 7,295 hospitalizations, 34,972 ED visits, 79,982 PO visits, and 614 deaths, generating 2,623 QALYs. RSVpreF reduced RSV-related direct medical costs by US$44 million (S/157 million). After vaccination costs and medical cost offsets, incremental costs were US$17 million (S/61 million), yielding an ICER of US$6,567/QALY (S/23,425), below Peru’s threshold of US$7,011/QALY (S/25,007).
CONCLUSIONS: RSVpreF is projected to reduce RSV-related clinical and economic burden and be cost-effective versus no vaccination among at-risk adults aged ≥60 years in Peru.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE602
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines